Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(1):21-28.
doi: 10.2174/1570162X15666171124122044.

The Neutralizing Antibody Response to the HIV-1 Env Protein

Penny L Moore  1   2   3
Affiliations
Review

The Neutralizing Antibody Response to the HIV-1 Env Protein

Penny L Moore. Curr HIV Res. 2018.

Abstract

Background: A vaccine able to elicit broadly neutralizing antibodies capable of blocking infection by global viruses has not been achieved, and remains a key public health challenge.

Objective: During infection, a robust strain-specific neutralizing response develops in most people, but only a subset of infected people develop broadly neutralizing antibodies. Understanding how and why these broadly neutralizing antibodies develop has been a focus of the HIV-1 vaccine field for many years, and has generated extraordinary insights into the neutralizing response to HIV-1 infection.

Results: This review describes the features, targets and developmental pathways of early strainspecific antibodies and later broadly neutralizing antibodies, and explores the reasons such broad antibodies are not more commonly elicited during infection.

Conclusion: The insights from these studies have been harnessed for the development of pioneering new vaccine approaches that seek to drive B cell maturation towards breadth. Overall, this review describes how findings from infected donors have impacted on active and passive immunization approaches that seek to prevent HIV-1 infection.

Keywords: HIV-1 envelope glycoprotein; broadly neutralizing antibodies; immunogens; passive immunity; viral escape; virus-host co-evolution..

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1).
Fig. (1).
Schematic depicting the timing of the development of binding antibodies, strain-specific Tier-2 neutralizing antibodies and broadly neutralizing antibodies.
Fig. (2).
Fig. (2).
Comparison of the development of broadly neutralizing antibodies in adults and children at approximately 5 years post-infection. Adapted from (26) and (30).
Fig. (3).
Fig. (3).
Co-evolutionary studies rely on i) bNAb isolation from HIV-1 infected donors, ii) next generation antibody sequencing to infer the evolutionary history of antibody lineages and iii) virological studies of escape pathways to define the role of viral evolution in shaping breadth. Adapted from [48, 69, 96].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhu P, Chertova E, Bess J Jr, et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003; 100: 15812–7. - PMC - PubMed
    1. Behrens AJ, Vasiljevic S, Pritchard LK, et al. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell reports 2016; 14: 2695–706. - PMC - PubMed
    1. Moore PL, Crooks ET, Porter L, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80: 2515–28. - PMC - PubMed
    1. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82: 12449–63. - PMC - PubMed
    1. Davis KL, Bibollet-Ruche F, Li H, et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2009; 83: 1240–59. - PMC - PubMed

Publication types

MeSH terms